Evolva Holding (CH:EVE)
:EVE
Top Page
Evolva Holding
(EVE)
Select Model
Select Model
Rating:42Neutral
Price Target:
CHF0.83
▲(0.73% Upside)
Action:ReiteratedDate:01/21/26
The score is held down primarily by weak financial performance (zero 2024 revenue and ongoing negative free cash flow), despite the benefit of a debt-free balance sheet and improved 2024 profitability. Technicals remain bearish with the stock trading below major moving averages, while valuation is difficult to support due to a negative P/E and no dividend yield data.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure materially lowers bankruptcy and interest-rate risk, preserving strategic optionality. Over 2–6 months this supports funding flexibility for R&D, licensing or pivot initiatives without immediate refinancing pressure, improving resilience.
Negative Factors
Revenue fell to zero in 2024
A complete loss of reported revenue is a structural business-model failure: without sustainable sales or recurring income, profitability and cash metrics are fragile. Over 2–6 months, absent new commercial traction this undermines credibility with partners and access to non-dilutive funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure materially lowers bankruptcy and interest-rate risk, preserving strategic optionality. Over 2–6 months this supports funding flexibility for R&D, licensing or pivot initiatives without immediate refinancing pressure, improving resilience.
Read all positive factors
Evolva Holding (EVE) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF6.42M
Dividend YieldN/A
Average Volume (3M)6.26K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue Growth-100.00%
EPS Growth97.27%
CountryCH
Employees49
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,230,626
10 Day Avg. Volume6,146
30 Day Avg. Volume6,263
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.5
Revenue Forecast (FY)CHF60.90M
Evolva Holding Business Overview & Revenue Model
Company Description
EvoNext Holdings SA engages in the business of researching, developing, and commercializing novel nutritional, healthcare, and wellness ingredients. The company was founded by Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith in ...
How the Company Makes Money
Evolva makes money primarily through the sale of its biosynthesized ingredients to businesses in the food, beverage, flavor, fragrance, and personal care industries. The company operates on a B2B model, partnering with major companies to incorpora...
Evolva Holding Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 9.44M | 15.54M | 9.88M | 7.54M |
| Gross Profit | 0.00 | 0.00 | -4.83M | -8.89M | -9.31M | -2.24M |
| EBITDA | 3.70M | 3.70M | -98.36M | -34.52M | -31.82M | -20.60M |
| Net Income | -851.20K | 1.04M | -105.23M | -43.37M | -41.27M | -29.87M |
Balance Sheet | ||||||
| Total Assets | 7.08M | 7.54M | 9.83M | 131.01M | 156.17M | 166.89M |
| Cash, Cash Equivalents and Short-Term Investments | 6.31M | 6.75M | 5.84M | 5.14M | 11.00M | 19.67M |
| Total Debt | 0.00 | 0.00 | 0.00 | 15.06M | 10.84M | 9.02M |
| Total Liabilities | 849.50K | 945.30K | 4.28M | 24.77M | 24.40M | 21.80M |
| Stockholders Equity | 6.24M | 6.60M | 5.55M | 106.24M | 131.77M | 145.09M |
Cash Flow | ||||||
| Free Cash Flow | -1.03M | -2.44M | -9.72M | -21.13M | -33.57M | -28.97M |
| Operating Cash Flow | -1.03M | -2.44M | -9.25M | -18.88M | -29.79M | -23.36M |
| Investing Cash Flow | 3.52M | 3.52M | 15.95M | -1.76M | -4.64M | -5.60M |
| Financing Cash Flow | -3.33M | -163.10K | -5.97M | 14.77M | 25.72M | 8.86M |
Evolva Holding Technical Analysis
Positive
0.82
Price Trends
0.87
Positive
0.85
Positive
0.93
Negative
Market Momentum
>-0.01
Negative
52.62
Neutral
85.19
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:EVE, the sentiment is Positive. The current price of 0.82 is below the 20-day moving average (MA) of 0.86, below the 50-day MA of 0.87, and below the 200-day MA of 0.93, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.62 is Neutral, neither overbought nor oversold. The STOCH value of 85.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:EVE.
Evolva Holding Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | CHF310.84M | -9.69 | ― | ― | 744.64% | ― | |
48 Neutral | CHF236.25M | -0.98 | -301.13% | ― | -56.85% | -186.55% | |
45 Neutral | CHF134.85M | -2.50 | -51.05% | ― | -100.00% | 14.45% | |
42 Neutral | CHF6.42M | -5.45 | -9.73% | ― | -100.00% | 97.27% |
* Healthcare Sector Average
CH:EVE
Evolva Holding
0.89
-0.24
-21.24%
CH:MOLN
Molecular Partners AG
3.34
0.25
8.09%
CH:NWRN
Newron Pharmaceuticals SpA
14.94
8.72
140.19%
CH:SANN
Santhera Pharmaceuticals Holding
16.64
3.38
25.49%
CH:XLS
Xlife Sciences Ltd.
21.50
2.50
13.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.